Immunotherapy has become a viable treatment option for brain tumors,
particularly gliomas and brain malignancies that have metastasized. This review
examines the clinical outcomes of recent clinical studies and the mechanisms by which
immunotherapy improves anti-tumor immune responses. Cancer vaccines, chimeric
antigen receptor (CAR) T-cell therapy and immune checkpoint inhibitors are important
tactics. Immune checkpoint inhibitors strengthen the natural defenses against cancer by
blocking proteins that hinder the immune system from attacking cancer cells. Through
the modulation of an individual's T cells to target particular cancer antigens, CAR Tcell treatment provides a customized course of treatment. The primary intent of cancer
vaccination is to prepare the host immune system for identifying and combating tumor
cells. Notwithstanding these developments, problems still exist. For example, the
blood-brain barrier limits the amount of medicinal entity that may reach the brain and
the tumor's immunosuppressive milieu impairs the activity of immune cells.
Combination therapies, which combine immunotherapy with conventional treatments
like radiation and chemotherapy, or employ numerous immunotherapeutic drugs, show
promise for overcoming these challenges. Approaches to personalized therapy that are
adapted to each patient's unique immunologic and genetic profile are also being
investigated to increase effectiveness and patient survival. Further research will be
needed to optimize these treatments and overcome their current limitations.
Immunotherapy possesses the ability to dramatically reinforce outcomes for individuals
with brain tumors, which are notoriously difficult to treat, by addressing the particular
difficulties that these malignancies present. It has shown promise in ameliorating brain
malignancies, particularly glioblastoma (GBM), but identifying biomarkers to predict
treatment outcomes remains a significant challenge. Prospective biomarkers, adoptive
cell transfer treatment, and novel drug delivery strategies are all being studied in current and upcoming clinical trials. There is optimism for improved GBM outcomes
with the introduction of novel drugs, such as immune checkpoint inhibitors, chimeric
antigen receptor (CAR) T-cell therapy, oncolytic virotherapy, and vaccination.
However, the fruitful utilization of immunotherapies for brain cancers requires the
improvement of biopsy collecting methods as well as the development of more
practical animal models.
Keywords: Brain tumors, BBB, CAR-T therapy, Immunotherapy.
